🚀 VC round data is live in beta, check it out!
Inotiv Valuation Multiples
Discover revenue and EBITDA valuation multiples for Inotiv and similar public comparables like ExpreS2ion Biotech, Mabion, WDB coco, J. Molner and more.
Inotiv Overview
About Inotiv
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Founded
1974
HQ
Employees
2.0K
Website
Financials (LTM)
EV
$474M
Inotiv Financials
Inotiv reported last 12-month revenue of $522M and EBITDA of $37M.
In the same LTM period, Inotiv generated $124M in gross profit, $37M in EBITDA, and had net loss of ($74M).
Revenue (LTM)
Inotiv P&L
In the most recent fiscal year, Inotiv reported revenue of $513M and EBITDA of $34M.
Inotiv expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $522M | XXX | $513M | XXX | XXX | XXX |
| Gross Profit | $124M | XXX | $121M | XXX | XXX | XXX |
| Gross Margin | 24% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $37M | XXX | $34M | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | (6%) | XXX | XXX | XXX |
| Net Profit | ($74M) | XXX | ($69M) | XXX | XXX | XXX |
| Net Margin | (14%) | XXX | (13%) | XXX | XXX | XXX |
| Net Debt | — | — | $383M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Inotiv Stock Performance
Inotiv has current market cap of $11M, and enterprise value of $474M.
Market Cap Evolution
Inotiv's stock price is $0.31.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $474M | $11M | 0.0% | XXX | XXX | XXX | $-2.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInotiv Valuation Multiples
Inotiv trades at 0.9x EV/Revenue multiple, and 13.0x EV/EBITDA.
EV / Revenue (LTM)
Inotiv Financial Valuation Multiples
As of April 8, 2026, Inotiv has market cap of $11M and EV of $474M.
Equity research analysts estimate Inotiv's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Inotiv has a P/E ratio of (0.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11M | XXX | $11M | XXX | XXX | XXX |
| EV (current) | $474M | XXX | $474M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 13.9x | XXX | XXX | XXX |
| EV/EBIT | (15.7x) | XXX | (15.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | (0.1x) | XXX | (0.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (17.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Inotiv Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Inotiv Margins & Growth Rates
Inotiv's revenue in the last 12 month grew by 4%.
Inotiv's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Inotiv's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Inotiv's rule of X is 17% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Inotiv Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 17% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 31% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Inotiv Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ExpreS2ion Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Mabion | XXX | XXX | XXX | XXX | XXX | XXX |
| WDB coco | XXX | XXX | XXX | XXX | XXX | XXX |
| J. Molner | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Inotiv M&A Activity
Inotiv acquired XXX companies to date.
Last acquisition by Inotiv was on XXXXXXXX, XXXXX. Inotiv acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Inotiv
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInotiv Investment Activity
Inotiv invested in XXX companies to date.
Inotiv made its latest investment on XXXXXXXX, XXXXX. Inotiv invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Inotiv
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Inotiv
| When was Inotiv founded? | Inotiv was founded in 1974. |
| Where is Inotiv headquartered? | Inotiv is headquartered in United States. |
| How many employees does Inotiv have? | As of today, Inotiv has over 2K employees. |
| Who is the CEO of Inotiv? | Inotiv's CEO is Robert W. Leasure. |
| Is Inotiv publicly listed? | Yes, Inotiv is a public company listed on Nasdaq. |
| What is the stock symbol of Inotiv? | Inotiv trades under NOTV ticker. |
| When did Inotiv go public? | Inotiv went public in 1997. |
| Who are competitors of Inotiv? | Inotiv main competitors are ExpreS2ion Biotech, Mabion, WDB coco, J. Molner. |
| What is the current market cap of Inotiv? | Inotiv's current market cap is $11M. |
| What is the current revenue of Inotiv? | Inotiv's last 12 months revenue is $522M. |
| What is the current revenue growth of Inotiv? | Inotiv revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Inotiv? | Current revenue multiple of Inotiv is 0.9x. |
| Is Inotiv profitable? | Yes, Inotiv is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Inotiv? | Inotiv's last 12 months EBITDA is $37M. |
| What is Inotiv's EBITDA margin? | Inotiv's last 12 months EBITDA margin is 7%. |
| What is the current EV/EBITDA multiple of Inotiv? | Current EBITDA multiple of Inotiv is 13.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.